504 related articles for article (PubMed ID: 35897648)
1. Targeting VIP and PACAP Receptor Signaling: New Insights into Designing Drugs for the PACAP Subfamily of Receptors.
Lu J; Piper SJ; Zhao P; Miller LJ; Wootten D; Sexton PM
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897648
[TBL] [Abstract][Full Text] [Related]
2. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
[TBL] [Abstract][Full Text] [Related]
3. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R
Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
[TBL] [Abstract][Full Text] [Related]
4. Backup Mechanisms Maintain PACAP/VIP-Induced Arterial Relaxations in Pituitary Adenylate Cyclase-Activating Polypeptide-Deficient Mice.
Ivic I; Fulop BD; Juhasz T; Reglodi D; Toth G; Hashimoto H; Tamas A; Koller A
J Vasc Res; 2017; 54(3):180-192. PubMed ID: 28490016
[TBL] [Abstract][Full Text] [Related]
5. Drug Repositioning For Allosteric Modulation of VIP and PACAP Receptors.
Langer I; Latek D
Front Endocrinol (Lausanne); 2021; 12():711906. PubMed ID: 34867774
[TBL] [Abstract][Full Text] [Related]
6. Characterization and expression of different pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptors in rat ovarian follicles.
Vaccari S; Latini S; Barberi M; Teti A; Stefanini M; Canipari R
J Endocrinol; 2006 Oct; 191(1):287-99. PubMed ID: 17065411
[TBL] [Abstract][Full Text] [Related]
7. Pituitary adenylate cyclase-activating polypeptide receptors mediating insulin secretion in rodent pancreatic islets are coupled to adenylate cyclase but not to PLC.
Jamen F; Puech R; Bockaert J; Brabet P; Bertrand G
Endocrinology; 2002 Apr; 143(4):1253-9. PubMed ID: 11897681
[TBL] [Abstract][Full Text] [Related]
8. Pituitary adenylate cyclase activating polypeptide: an important vascular regulator in human skin in vivo.
Seeliger S; Buddenkotte J; Schmidt-Choudhury A; Rosignoli C; Shpacovitch V; von Arnim U; Metze D; Rukwied R; Schmelz M; Paus R; Voegel JJ; Schmidt WE; Steinhoff M
Am J Pathol; 2010 Nov; 177(5):2563-75. PubMed ID: 20889562
[TBL] [Abstract][Full Text] [Related]
9. Pituitary adenylate cyclase-activating polypeptide promotes eccrine gland sweat secretion.
Sasaki S; Watanabe J; Ohtaki H; Matsumoto M; Murai N; Nakamachi T; Hannibal J; Fahrenkrug J; Hashimoto H; Watanabe H; Sueki H; Honda K; Miyazaki A; Shioda S
Br J Dermatol; 2017 Feb; 176(2):413-422. PubMed ID: 27453364
[TBL] [Abstract][Full Text] [Related]
10. Cardioprotective role of the VIP signaling system.
Dvoráková MC
Timely Top Med Cardiovasc Dis; 2005 Oct; 9():E33. PubMed ID: 16341283
[TBL] [Abstract][Full Text] [Related]
11. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
Akesson L; Ahrén B; Edgren G; Degerman E
Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
[TBL] [Abstract][Full Text] [Related]
12. [Physiological significance of pituitary adenylate cyclase-activating polypeptide (PACAP) in the nervous system].
Hashimoto H
Yakugaku Zasshi; 2002 Dec; 122(12):1109-21. PubMed ID: 12510388
[TBL] [Abstract][Full Text] [Related]
13. Understanding VPAC receptor family peptide binding and selectivity.
Piper SJ; Deganutti G; Lu J; Zhao P; Liang YL; Lu Y; Fletcher MM; Hossain MA; Christopoulos A; Reynolds CA; Danev R; Sexton PM; Wootten D
Nat Commun; 2022 Nov; 13(1):7013. PubMed ID: 36385145
[TBL] [Abstract][Full Text] [Related]
14. Vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide receptor chimeras reveal domains that determine specificity of vasoactive intestinal polypeptide binding and activation.
Hashimoto H; Ogawa N; Hagihara N; Yamamoto K; Imanishi K; Nogi H; Nishino A; Fujita T; Matsuda T; Nagata S; Baba A
Mol Pharmacol; 1997 Jul; 52(1):128-35. PubMed ID: 9224822
[TBL] [Abstract][Full Text] [Related]
15. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions.
Vaudry D; Gonzalez BJ; Basille M; Yon L; Fournier A; Vaudry H
Pharmacol Rev; 2000 Jun; 52(2):269-324. PubMed ID: 10835102
[TBL] [Abstract][Full Text] [Related]
16. Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer.
Moody TW; Nuche-Berenguer B; Jensen RT
Curr Opin Endocrinol Diabetes Obes; 2016 Feb; 23(1):38-47. PubMed ID: 26702849
[TBL] [Abstract][Full Text] [Related]
17. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate.
Solano RM; Carmena MJ; Carrero I; Cavallaro S; Roman F; Hueso C; Travali S; Lopez-Fraile N; Guijarro LG; Prieto JC
Endocrinology; 1996 Jul; 137(7):2815-22. PubMed ID: 8770902
[TBL] [Abstract][Full Text] [Related]
18. Expression of mRNAs for PACAP and its receptor in human neuroblastomas and their relationship to catecholamine synthesis.
Isobe K; Kaneko M; Kaneko S; Nissato S; Nanmoku T; Takekoshi K; Okuda Y; Kawakami Y
Regul Pept; 2004 Dec; 123(1-3):29-32. PubMed ID: 15518890
[TBL] [Abstract][Full Text] [Related]
19. Identification and functional properties of the pituitary adenylate cyclase activating peptide (PAC1) receptor in human benign hyperplastic prostate.
Solano RM; Carmena MJ; Busto R; Sánchez-Chapado M; Guijarro LG; Prieto JC
Cell Signal; 1999 Nov; 11(11):813-9. PubMed ID: 10617284
[TBL] [Abstract][Full Text] [Related]
20. Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems.
Arimura A
Jpn J Physiol; 1998 Oct; 48(5):301-31. PubMed ID: 9852340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]